Business Context and Reporting Period
This Form 8-K Current Report was filed by JetBlue Airways Corporation on January 22, 2021, covering events occurring on January 15, 2021. The filing details the company's entry into new material definitive agreements with the U.S. Department of the Treasury regarding federal payroll support and loan facility amendments.
Key Financial Metrics and Agreements
- Payroll Support Program 2 Payment: Received approximately $252 million total, consisting of a $206 million grant and a $46 million loan.
- Debt Terms: The $46 million loan is evidenced by a promissory note maturing 10 years from issuance (January 15, 2031). Interest is 1.00% annually until January 15, 2026, then Applicable SOFR Rate plus 2.00%.
- Equity Dilution: Issued warrants to the Treasury to purchase 316,583 shares of common stock at an exercise price of $14.43 per share. Warrants expire five years from issuance.
- Additional Funding Potential: JetBlue may be entitled to an additional disbursement of up to $252 million, including a loan of up to $76 million, contingent on further terms.
- CARES Act Loan Facility: The borrowing deadline for the existing secured term loan facility (increased to $1.95 billion in November 2020) was extended from March 26, 2021, to May 28, 2021.
Material Changes Versus Prior Period
This filing represents a continuation of federal support received in April and September 2020 under the CARES Act. The primary material change is the execution of the Payroll Support Program 2 Extension Agreement, which provides new liquidity ($252 million) and modifies the capital structure through new debt and warrant issuance. Additionally, the extension of the borrowing deadline for the CARES Act Loan Agreement provides increased flexibility for future drawdowns compared to the previous March 2021 deadline.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding operational performance. The primary risk and contingency noted is the obligation to repay the $46 million loan with interest and the potential dilution from the exercise of the 316,583 warrants. The terms of the new agreements are materially identical to those of the Initial Payroll Support Payment.
Investor Verification Checklist
- Verify the exact split between the grant portion ($206 million) and the loan portion ($46 million) in the company's cash flow statement.
- Confirm the impact of the 316,583 warrants on fully diluted share count and potential dilution at the $14.43 exercise price.
- Monitor the company's utilization of the extended borrowing window (through May 28, 2021) for the CARES Act Loan Agreement.
- Review the interest rate reset mechanism (SOFR + 2.00%) applicable after January 15, 2026, for long-term debt cost projections.